Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozibafusp Alfa in Active SLE
NCT04058028Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2020
- Primary completion
- Jul 2023
- Modality
- Bispecific Antibodies, Peptides
- Countries
- 19
01
Overview
A Phase 2 trial of rozibafusp alfa in systemic lupus erythematosus (SLE), sponsored by Amgen. Started Feb 2020; status: completed.
02
Drugs
rozibafusp alfa
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04058028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058028.